Syros Pharmaceuticals Inc (NASDAQ:SYRS) insider Jeremy P. Springhorn acquired 15,000 shares of Syros Pharmaceuticals stock in a transaction that occurred on Friday, December 15th. The stock was acquired at an average cost of $9.08 per share, with a total value of $136,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Syros Pharmaceuticals Inc (NASDAQ SYRS) opened at $8.99 on Friday. Syros Pharmaceuticals Inc has a twelve month low of $6.30 and a twelve month high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its earnings results on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, hitting the consensus estimate of ($0.53). sell-side analysts predict that Syros Pharmaceuticals Inc will post -2.12 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth about $240,000. Cubist Systematic Strategies LLC bought a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth about $149,000. Schwab Charles Investment Management Inc. increased its holdings in shares of Syros Pharmaceuticals by 95.8% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 41,709 shares of the company’s stock worth $614,000 after purchasing an additional 20,409 shares during the period. Citadel Advisors LLC bought a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth about $975,000. Finally, Trexquant Investment LP bought a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth about $282,000. Hedge funds and other institutional investors own 58.02% of the company’s stock.

Several equities research analysts recently issued reports on SYRS shares. Roth Capital started coverage on shares of Syros Pharmaceuticals in a research note on Monday, October 23rd. They issued a “neutral” rating and a $15.00 price objective for the company. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Syros Pharmaceuticals in a research note on Tuesday, October 31st. ValuEngine lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 22nd. Zacks Investment Research raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Finally, JMP Securities raised shares of Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price objective for the company in a research note on Thursday, September 28th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $26.14.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/jeremy-p-springhorn-buys-15000-shares-of-syros-pharmaceuticals-inc-syrs-stock/1769734.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.